$TDOC
Teladoc Health, Inc. Stock $tdoc

$tdoc Overview Financials Valuation SEC Filings Company Website

2020 Form 10-K Financial Statement

#000155837021002118 Filed on March 01, 2021

Income Statement

Concept	2020	2019 Q4	2019
Revenue	$1.094B	$156.5M	$553.3M
YoY Change	97.71%	27.5%	32.4%
Cost Of Revenue	$390.8M	$55.36M	$184.5M
YoY Change	111.87%	38.29%	43.29%
Gross Profit	$703.1M	$101.1M	$368.8M
YoY Change	90.63%	22.27%	27.55%
Gross Profit Margin	64.27%	64.63%	66.66%
Selling, General & Admin	$660.7M	$61.23M	$229.4M
YoY Change	188.06%	20.14%	30.27%
% of Gross Profit	93.97%	60.55%	62.19%
Research & Development	$164.9M	$16.25M	$64.64M
YoY Change	155.15%	19.95%	18.89%
% of Gross Profit	23.46%	16.06%	17.53%
Depreciation & Amortization	$69.50M	$11.09M	$38.95M
YoY Change	78.41%	16.13%	9.41%
% of Gross Profit	9.88%	10.97%	10.56%
Operating Expenses	$825.7M	$77.48M	$294.0M
YoY Change	180.83%	20.1%	27.59%
Operating Profit	-$506.4M	-$15.59M	-$80.44M
YoY Change	529.55%	-12.61%	13.53%
Interest Expense	-$60.50M	-$7.600M	-$29.00M
YoY Change	108.62%	13.43%	11.11%
% of Operating Profit
Other Income/Expense, Net	-$545.0K		$342.0K
YoY Change	-259.36%
Pretax Income	-$576.0M	-$23.17M	-$109.5M
YoY Change	426.24%	-5.43%	12.88%
Income Tax	-$90.86M	-$4.125M	-$10.59M
% Of Pretax Income
Net Earnings	-$485.1M	-$19.04M	-$98.86M
YoY Change	390.71%	-23.45%	1.83%
Net Earnings / Revenue	-44.35%	-12.17%	-17.87%
Basic Earnings Per Share	-$5.36		-$1.38
Diluted Earnings Per Share	-$5.36	-$261.7K	-$1.38
COMMON SHARES
Basic Shares Outstanding	90.51M	72.38M	71.85M
Diluted Shares Outstanding	90.51M		71.85M

Balance Sheet

Concept	2020	2019 Q4	2019
SHORT-TERM ASSETS
Cash & Short-Term Investments	$787.0M	$517.1M	$517.0M
YoY Change	52.22%	8.05%	7.93%
Cash & Equivalents	$733.0M	$514.4M	$514.0M
Short-Term Investments	$53.00M	$2.711M	$3.000M
Other Short-Term Assets	$47.00M	$14.00M	$14.00M
YoY Change	235.71%	27.27%	27.27%
Inventory	$56.00M	$0.00
Prepaid Expenses
Receivables	$169.0M	$56.95M	$57.00M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.060B	$588.0M	$588.0M
YoY Change	80.27%	10.37%	10.32%
LONG-TERM ASSETS
Property, Plant & Equipment	$75.00M	$10.30M	$37.00M
YoY Change	102.7%	1.46%	270.0%
Goodwill		$746.1M
YoY Change		1.2%
Intangibles		$225.5M
YoY Change		-8.87%
Long-Term Investments
YoY Change
Other Assets	$18.00M	$6.545M	$7.000M
YoY Change	157.14%	367.17%	600.0%
Total Long-Term Assets	$16.70B	$1.015B	$1.015B
YoY Change	1544.83%	1.88%	1.91%
TOTAL ASSETS
Total Short-Term Assets	$1.060B	$588.0M	$588.0M
Total Long-Term Assets	$16.70B	$1.015B	$1.015B
Total Assets	$17.76B	$1.603B	$1.603B
YoY Change	1007.61%	4.84%	4.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$46.00M	$9.075M	$9.000M
YoY Change	411.11%	16.81%	12.5%
Accrued Expenses	$156.0M	$58.00M	$58.00M
YoY Change	168.97%	41.46%	41.46%
Deferred Revenue		$12.47M
YoY Change		62.95%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$56.00M	$0.00
YoY Change
Total Short-Term Liabilities	$333.0M	$90.18M	$90.00M
YoY Change	270.0%	44.43%	45.16%
LONG-TERM LIABILITIES
Long-Term Debt	$1.390B	$440.0M	$440.0M
YoY Change	215.91%	6.02%	6.02%
Other Long-Term Liabilities	$47.00M	$9.239M	$37.00M
YoY Change	27.03%	49.23%	516.67%
Total Long-Term Liabilities	$1.437B	$9.239M	$477.0M
YoY Change	201.26%	49.23%	13.3%
TOTAL LIABILITIES
Total Short-Term Liabilities	$333.0M	$90.18M	$90.00M
Total Long-Term Liabilities	$1.437B	$9.239M	$477.0M
Total Liabilities	$1.871B	$99.42M	$589.0M
YoY Change	217.66%	44.86%	14.15%
SHAREHOLDERS EQUITY
Retained Earnings		-$507.5M
YoY Change		24.19%
Common Stock		$1.539B
YoY Change		7.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$15.88B	$1.014B	$1.014B
YoY Change
Total Liabilities & Shareholders Equity	$17.76B	$1.603B	$1.603B
YoY Change	1007.61%	4.84%	4.84%

Cashflow Statement

Concept	2020	2019 Q4	2019
OPERATING ACTIVITIES
Net Income	-$485.1M	-$19.04M	-$98.86M
YoY Change	390.71%	-23.45%	1.83%
Depreciation, Depletion And Amortization	$69.50M	$11.09M	$38.95M
YoY Change	78.41%	16.13%	9.41%
Cash From Operating Activities	-$53.51M	$18.12M	$29.87M
YoY Change	-279.15%	630.65%	-714.59%
INVESTING ACTIVITIES
Capital Expenditures	$4.024M	-$3.390M	$3.510M
YoY Change	14.64%	16.1%	-12.49%
Acquisitions	$567.4M		$11.19M
YoY Change	4972.22%		-96.04%
Other Investing Activities	$0.00	$12.94M	$0.00
YoY Change		-132.82%	-100.0%
Cash From Investing Activities	-$591.0M	$9.540M	$25.01M
YoY Change	-2462.67%	-122.53%	-109.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00		$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net			$0.00
YoY Change
Cash From Financing Activities	859.1M	10.04M	35.09M
YoY Change	2348.1%	34.77%	-94.56%
NET CHANGE
Cash From Operating Activities	-53.51M	18.12M	29.87M
Cash From Investing Activities	-591.0M	9.540M	25.01M
Cash From Financing Activities	859.1M	10.04M	35.09M
Net Change In Cash	214.7M	37.70M	89.98M
YoY Change	138.56%	-216.29%	-76.52%
FREE CASH FLOW
Cash From Operating Activities	-$53.51M	$18.12M	$29.87M
Capital Expenditures	$4.024M	-$3.390M	$3.510M
Free Cash Flow	-$57.54M	$21.51M	$26.36M
YoY Change	-318.27%	298.33%	-397.14%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:OperatingLeaseLiabilityCurrent
CY2019Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2020Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2019Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2020Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2019Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2020Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet	0
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet	0
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet	0
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet	0
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001477449
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	150281099
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	72761941
CY2020	tdoc	Number Of Service Corporations Consolidated As Variable Interest Entities NumberOfServiceCorporationsConsolidatedAsVariableInterestEntities	1
CY2020Q4	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	us-gaap:OperatingLeaseLiability
CY2020Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P12M
CY2020Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P12M
CY2019Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:OperatingLeaseLiabilityCurrent
CY2020Q4	tdoc	Exercise Price Adjustment Ratio Closing Price Threshold Trading Days ExercisePriceAdjustmentRatioClosingPriceThresholdTradingDays	P4D
CY2020Q4	tdoc	Exercise Price Adjustment Ratio Closing Price Threshold Trading Days ExercisePriceAdjustmentRatioClosingPriceThresholdTradingDays	P4D
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-37477
CY2020	dei	Entity Registrant Name EntityRegistrantName	TELADOC HEALTH, INC.
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020Q2	dei	Entity Public Float EntityPublicFloat	14936555578
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	152699999
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3705970
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	733324000
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	2 Manhattanville Road
CY2020	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 203
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Purchase
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10577
CY2020	dei	City Area Code CityAreaCode	203
CY2020	dei	Local Phone Number LocalPhoneNumber	635-2002
CY2020	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2020	dei	Trading Symbol TradingSymbol	TDOC
CY2020	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	false
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	514353000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	53245000
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	2711000
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	6412000
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	3787000
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	169281000
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	56948000
CY2020Q4	us-gaap	Inventory Net InventoryNet	56498000
CY2019Q4	us-gaap	Inventory Net InventoryNet	0
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	47259000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13990000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	1059607000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	588002000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28551000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10296000
CY2020Q4	us-gaap	Goodwill Goodwill	14581255000
CY2019Q4	us-gaap	Goodwill Goodwill	746079000
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2020864000
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	225453000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	46647000
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	26452000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18357000
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6545000
CY2020Q4	us-gaap	Assets Assets	17755281000
CY2019Q4	us-gaap	Assets Assets	1602827000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	46030000
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9075000
CY2020Q4	tdoc	Accrued Liabilities And Other Liabilities Excluding Accrued Compensation Current AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent	83657000
CY2019Q4	tdoc	Accrued Liabilities And Other Liabilities Excluding Accrued Compensation Current AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent	34440000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	94593000
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	34201000
CY2020Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	52356000
CY2019Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	12465000
CY2020Q4	tdoc	Advances From Financing Companies Current AdvancesFromFinancingCompaniesCurrent	13453000
CY2019Q4	tdoc	Advances From Financing Companies Current AdvancesFromFinancingCompaniesCurrent	0
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	42560000
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	332649000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	90181000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1616000
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9239000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	43142000
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	24994000
CY2020Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2449000
CY2019Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2300000
CY2020Q4	tdoc	Advances From Financing Companies Noncurrent AdvancesFromFinancingCompaniesNoncurrent	9926000
CY2019Q4	tdoc	Advances From Financing Companies Noncurrent AdvancesFromFinancingCompaniesNoncurrent	0
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	102103000
CY2019Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	21678000
CY2020Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	1379592000
CY2019Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	440410000
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	150281099
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	72761941
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	150000
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	73000
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	16857797000
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1538716000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-992661000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-507525000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	18518000
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-17239000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	15883804000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	1014025000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17755281000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1602827000
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1093962000
CY2019	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	553307000
CY2018	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	417907000
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	390829000
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	184465000
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	128735000
CY2020	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	226146000
CY2019	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	109697000
CY2018	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	85109000
CY2020	us-gaap	Selling Expense SellingExpense	154052000
CY2019	us-gaap	Selling Expense SellingExpense	64915000
CY2018	us-gaap	Selling Expense SellingExpense	59154000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	164941000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	64644000
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	54373000
CY2020	tdoc	Legal And Regulatory Expense LegalAndRegulatoryExpense	8876000
CY2019	tdoc	Legal And Regulatory Expense LegalAndRegulatoryExpense	6762000
CY2018	tdoc	Legal And Regulatory Expense LegalAndRegulatoryExpense	3981000
CY2020	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	88236000
CY2019	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	6620000
CY2018	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	10391000
CY2020	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0
CY2019	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0
CY2018	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	5500000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	497808000
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	157694000
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	116916000
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	69495000
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	38952000
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	35602000
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	1600383000
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	633749000
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	488761000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-506421000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-80442000
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-70854000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-9077000
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2020	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-60495000
CY2019	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-29013000
CY2018	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-26112000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-575993000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-109455000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-96966000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-90857000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-10591000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	118000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-485136000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-98864000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-97084000
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.36
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.38
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.47
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	90509229
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	71844535
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	65844908
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-485136000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-98864000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-97084000
CY2020	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0
CY2019	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	32000
CY2018	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	20000
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	35757000
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-4201000
CY2018	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-17179000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	35757000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-4169000
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-17159000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-449379000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-103033000
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-114243000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	558903000
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	31322000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	91397000
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	330843000
CY2018	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2564000
CY2018	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	68564000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	43769000
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-17159000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-97084000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	1013119000
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	33275000
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3380000
CY2019	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	8000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	67276000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-4169000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-98864000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	1014025000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	54314000
CY2020	tdoc	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	-23705000
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	4722000
CY2020	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	13884921000
CY2020	tdoc	Adjustments To Additional Paid In Capital Sale Of Capped Call Related To Livongo Notes AdjustmentsToAdditionalPaidInCapitalSaleOfCappedCallRelatedToLivongoNotes	91659000
CY2020	tdoc	Adjustments To Additional Paid In Capital Livongo Notes Guaranteed By Company AdjustmentsToAdditionalPaidInCapitalLivongoNotesGuaranteedByCompany	555448000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	478204000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	35757000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-485136000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	15883804000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-485136000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-98864000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-97084000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	69495000
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	38952000
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	35602000
CY2020	tdoc	Depreciation Of Rental Equipment DepreciationOfRentalEquipment	1697000
CY2019	tdoc	Depreciation Of Rental Equipment DepreciationOfRentalEquipment	0
CY2018	tdoc	Depreciation Of Rental Equipment DepreciationOfRentalEquipment	0
CY2020	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	6895000
CY2019	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	6000000
CY2018	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	0
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	5284000
CY2019	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	2665000
CY2018	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	2243000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	475531000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	66702000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	43769000
CY2020	tdoc	Deferred Income Tax Noncash Expense Benefit DeferredIncomeTaxNoncashExpenseBenefit	-90158000
CY2019	tdoc	Deferred Income Tax Noncash Expense Benefit DeferredIncomeTaxNoncashExpenseBenefit	-10868000
CY2018	tdoc	Deferred Income Tax Noncash Expense Benefit DeferredIncomeTaxNoncashExpenseBenefit	-2247000
CY2020	tdoc	Accretion Of Interest AccretionOfInterest	45296000
CY2019	tdoc	Accretion Of Interest AccretionOfInterest	25438000
CY2018	tdoc	Accretion Of Interest AccretionOfInterest	19487000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-9077000
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2020	tdoc	Change In Fair Value Contingent Consideration ChangeInFairValueContingentConsideration	1009000
CY2019	tdoc	Change In Fair Value Contingent Consideration ChangeInFairValueContingentConsideration	-1248000
CY2018	tdoc	Change In Fair Value Contingent Consideration ChangeInFairValueContingentConsideration	0
CY2020	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0
CY2019	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0
CY2018	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	5500000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	21091000
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	15884000
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10931000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	12565000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2685000
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2612000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	24732000
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	8135000
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	105000
CY2018	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	414000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-87995000
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	905000
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-391000
CY2020	tdoc	Increase Decrease In Accrued Liabilities And Other Current Liabilities Excluding Accrued Compensation IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilitiesExcludingAccruedCompensation	20125000
CY2019	tdoc	Increase Decrease In Accrued Liabilities And Other Current Liabilities Excluding Accrued Compensation IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilitiesExcludingAccruedCompensation	10026000
CY2018	tdoc	Increase Decrease In Accrued Liabilities And Other Current Liabilities Excluding Accrued Compensation IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilitiesExcludingAccruedCompensation	454000
CY2020	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	34819000
CY2019	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	4546000
CY2018	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	8480000
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	17751000
CY2019	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	4815000
CY2018	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	3539000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3510000
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4011000
CY2020	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	22018000
CY2019	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	7390000
CY2018	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	4396000
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0
CY2019	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0
CY2018	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	56347000
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2496000
CY2019	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	52100000
CY2018	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	84170000
CY2020	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0
CY2020	tdoc	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-6300000
CY2019	tdoc	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-2417000
CY2018	tdoc	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	0
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-2360000
CY2019	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-605000
CY2018	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	745000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-53511000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	29869000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4860000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4024000
CY2019	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0
CY2018	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	5530000
CY2020	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	0
CY2019	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	5000000
CY2018	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	0
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	567429000
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	11187000
CY2018	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	282442000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-590975000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	25013000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-257496000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	54314000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	33283000
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	31322000
CY2020	tdoc	Proceeds From Sale Of Capped Call Related To Livongo Notes ProceedsFromSaleOfCappedCallRelatedToLivongoNotes	91659000
CY2019	tdoc	Proceeds From Sale Of Capped Call Related To Livongo Notes ProceedsFromSaleOfCappedCallRelatedToLivongoNotes	0
CY2018	tdoc	Proceeds From Sale Of Capped Call Related To Livongo Notes ProceedsFromSaleOfCappedCallRelatedToLivongoNotes	0
CY2020	tdoc	Proceeds From Advances From Financing Companies ProceedsFromAdvancesFromFinancingCompanies	6002000
CY2019	tdoc	Proceeds From Advances From Financing Companies ProceedsFromAdvancesFromFinancingCompanies	0
CY2018	tdoc	Proceeds From Advances From Financing Companies ProceedsFromAdvancesFromFinancingCompanies	0
CY2020	tdoc	Payments From Customers Against Advances From Financing Companies PaymentsFromCustomersAgainstAdvancesFromFinancingCompanies	8635000
CY2019	tdoc	Payments From Customers Against Advances From Financing Companies PaymentsFromCustomersAgainstAdvancesFromFinancingCompanies	0
CY2018	tdoc	Payments From Customers Against Advances From Financing Companies PaymentsFromCustomersAgainstAdvancesFromFinancingCompanies	0
CY2020	us-gaap	Repayments Of Assumed Debt RepaymentsOfAssumedDebt	10000000
CY2019	us-gaap	Repayments Of Assumed Debt RepaymentsOfAssumedDebt	0
CY2018	us-gaap	Repayments Of Assumed Debt RepaymentsOfAssumedDebt	0
CY2020	tdoc	Proceeds From Issuance Of Bank And Other Debt ProceedsFromIssuanceOfBankAndOtherDebt	0
CY2020	tdoc	Cash Related To Tax Withholding For Share Based Compensation Net CashRelatedToTaxWithholdingForShareBasedCompensationNet	-26703000
CY2019	tdoc	Cash Related To Tax Withholding For Share Based Compensation Net CashRelatedToTaxWithholdingForShareBasedCompensationNet	-1569000
CY2018	tdoc	Cash Related To Tax Withholding For Share Based Compensation Net CashRelatedToTaxWithholdingForShareBasedCompensationNet	1721000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	859136000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	35094000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	645612000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	214650000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	89976000
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	383256000
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4321000
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	388000
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-2084000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	514353000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	423989000
CY2019	tdoc	Proceeds From Issuance Of Bank And Other Debt ProceedsFromIssuanceOfBankAndOtherDebt	0
CY2018	tdoc	Proceeds From Issuance Of Bank And Other Debt ProceedsFromIssuanceOfBankAndOtherDebt	10000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	330843000
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	4722000
CY2019	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	3380000
CY2018	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	2564000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	42817000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	733324000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	514353000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	423989000
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1324000
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1310000
CY2018	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	441000
CY2020	us-gaap	Interest Paid InterestPaid	14890000
CY2019	us-gaap	Interest Paid InterestPaid	12224000
CY2018	us-gaap	Interest Paid InterestPaid	10303000
CY2020	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">TELADOC HEALTH, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes to Audited Consolidated Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Note 1. Organization and Description of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Teladoc, Inc. was incorporated in the State of Texas in June 2002 and changed its state of incorporation to the State of Delaware in October 2008. Effective August 10, 2018, Teladoc, Inc. changed its corporate name to Teladoc Health, Inc. Unless the context otherwise requires, Teladoc Health, Inc., together with its subsidiaries, is referred to herein as “Teladoc Health” or the “Company”. The Company’s principal executive office is located in Purchase, New York. Teladoc Health is the global leader in providing virtual healthcare services with a focus on high quality, lower costs, and improved outcomes around the world. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">On October 30, 2020, the Company completed the merger with Livongo Health, Inc. (“Livongo”), a transformational opportunity to improve the delivery, access and experience of healthcare for consumers around the world. Livongo is pioneering a new category in healthcare, called Applied Health Signals, which is transforming the management of chronic conditions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">On July 1, 2020, the Company completed the acquisition of InTouch Technologies, Inc. (“InTouch”), the leading provider of enterprise telehealth solutions for hospitals and health systems.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">On April 30, 2019, the Company completed the acquisition of MedecinDirect, a Paris-based telemedicine provider.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">On May 31, 2018, the Company completed the acquisition of Advance Medical-Health Care Management Services, S.A. (“Advance Medical”), a leading virtual healthcare provider outside the United States. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">On July 14, 2017, the Company completed the acquisition of Best Doctors Holdings, Inc. (“Best Doctors”), an expert medical consultation company focused on improving health outcomes for the most complex, critical and costly medical issues.</p>
CY2020	tdoc	Contract With Customer Term ContractWithCustomerTerm	P1Y
CY2020	tdoc	Number Of Professional Associations Consolidated As Variable Interest Entities NumberOfProfessionalAssociationsConsolidatedAsVariableInterestEntities	3
CY2020	tdoc	Number Of Professional Corporations Consolidated As Variable Interest Entities NumberOfProfessionalCorporationsConsolidatedAsVariableInterestEntities	12
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, current business factors, and various other assumptions that the Company believes are necessary to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and the disclosure of contingent assets and liabilities. The Company is subject to uncertainties such as the impact of future events, economic and political factors, and changes in the Company’s business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of the Company’s consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Company’s operating environment evolves. The Company believes that estimates used in the preparation of these consolidated financial statements are reasonable; however, actual results could differ materially from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in reported results of operations; if material, the effects of changes in estimates are disclosed in the notes to the consolidated financial statements. Significant estimates and assumptions by management affect the allowance for doubtful accounts, the carrying value of long-lived assets (including goodwill and intangible assets), capitalization and amortization of software development costs, the finalization of purchase accounting adjustments, Client performance guarantees, the calculation of a contingent liability in connection with an acquisition earn-out, the provision for income taxes and related deferred tax accounts, certain accrued liabilities, revenue </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">recognition, contingencies, litigation and related legal accruals and the value attributed to employee stock options and other stock-based awards and the periods of benefit for deferred costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;"></span></p>
CY2020	tdoc	Payment Terms PaymentTerms	P30D
CY2020	tdoc	Contract With Customer Refunds Issued ContractWithCustomerRefundsIssued	11200000
CY2019	tdoc	Contract With Customer Refunds Issued ContractWithCustomerRefundsIssued	3600000
CY2018	tdoc	Contract With Customer Refunds Issued ContractWithCustomerRefundsIssued	3000000.0
CY2020	tdoc	Contract With Customer Liability Increase Decrease For Change In Estimate Of Transaction Price And Change In Client Performance Guarantees ContractWithCustomerLiabilityIncreaseDecreaseForChangeInEstimateOfTransactionPriceAndChangeInClientPerformanceGuarantees	1900000
CY2019	tdoc	Contract With Customer Liability Increase Decrease For Change In Estimate Of Transaction Price And Change In Client Performance Guarantees ContractWithCustomerLiabilityIncreaseDecreaseForChangeInEstimateOfTransactionPriceAndChangeInClientPerformanceGuarantees	800000
CY2018	tdoc	Contract With Customer Liability Increase Decrease For Change In Estimate Of Transaction Price And Change In Client Performance Guarantees ContractWithCustomerLiabilityIncreaseDecreaseForChangeInEstimateOfTransactionPriceAndChangeInClientPerformanceGuarantees	800000
CY2020	tdoc	Amortization Term Of Deferred Contract Cost AmortizationTermOfDeferredContractCost	P4Y
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	62600000
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	200000
CY2018	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2020	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-600000
CY2018	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-100000
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1093962000
CY2019	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	553307000
CY2018	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	417907000
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	40000000
CY2020	us-gaap	Advertising Expense AdvertisingExpense	165000000.0
CY2019	us-gaap	Advertising Expense AdvertisingExpense	88800000
CY2018	us-gaap	Advertising Expense AdvertisingExpense	70600000
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Concentrations of Risk </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents, short-term investments and accounts receivable. Although the Company deposits its cash with multiple financial institutions in the U.S. and in foreign countries, its deposits, at times, may exceed federally insured limits. The Company’s short-term investments are comprised of a portfolio of diverse high credit rating instruments with maturity durations of one year or less.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:10pt 0pt 0pt 0pt;">No Client represented over 10% of revenues for the years ended December 31, 2020, 2019 or 2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:10pt 0pt 0pt 0pt;">No Client represented over 10% of accounts receivable at December 31, 2020 or 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Revenue from Clients located in the United States for the year ended December 31, 2020, 2019 and 2018 were $967.4 million, $445.3 million and $342.7 million, respectively. Revenue from Clients located outside the United States for the year ended December 31, 2020, 2019 and 2018 were $126.6 million, $108.0 million, and $75.2 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;"></span></p>
CY2020	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Reclassifications</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Certain prior year amounts have been reclassified to conform to the current year presentation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;"></span></p>
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	7100000
CY2020Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Deferred Revenue BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue	21700000
CY2020	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	12500000
CY2019	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	7100000
CY2020Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	52400000
CY2020Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	2000000.0
CY2020Q4	tdoc	Deferred Device Cost And Other Current DeferredDeviceCostAndOtherCurrent	3384000
CY2020Q4	tdoc	Deferred Device Cost And Other Non Current DeferredDeviceCostAndOtherNonCurrent	2179000
CY2020Q4	tdoc	Deferred Device Cost And Other DeferredDeviceCostAndOther	5563000
CY2019Q4	tdoc	Deferred Device Cost And Other DeferredDeviceCostAndOther	0
CY2020	tdoc	Deferred Device Cost And Other Additions DeferredDeviceCostAndOtherAdditions	6007000
CY2020	tdoc	Deferred Device Cost And Other Revenue Recognized DeferredDeviceCostAndOtherRevenueRecognized	-444000
CY2020Q4	tdoc	Deferred Device Cost And Other DeferredDeviceCostAndOther	5563000
CY2019Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2020Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2020Q4	us-gaap	Inventory Raw Materials And Purchased Parts Net Of Reserves InventoryRawMaterialsAndPurchasedPartsNetOfReserves	19591000
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1431000
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	35476000
CY2020Q4	us-gaap	Inventory Net InventoryNet	56498000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	196019000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	186860000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	188386000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	183409000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1266190000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2020864000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	50516000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	26058000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	21965000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15762000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28551000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10296000
CY2020	us-gaap	Depreciation Depreciation	4800000
CY2019	us-gaap	Depreciation Depreciation	3400000
CY2018	us-gaap	Depreciation Depreciation	4100000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2183399000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	162535000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2020864000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	319796000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	94343000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	225453000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	64700000
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	35600000
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	31500000
CY2019Q4	us-gaap	Goodwill Goodwill	746079000
CY2018Q4	us-gaap	Goodwill Goodwill	737197000
CY2020	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	13812198000
CY2019	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	10604000
CY2020	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	22978000
CY2019	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-1722000
CY2020Q4	us-gaap	Goodwill Goodwill	14581255000
CY2019Q4	us-gaap	Goodwill Goodwill	746079000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4717000
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1535000
CY2020Q4	tdoc	Accrued Consulting And Customer Service Fees Current AccruedConsultingAndCustomerServiceFeesCurrent	23167000
CY2019Q4	tdoc	Accrued Consulting And Customer Service Fees Current AccruedConsultingAndCustomerServiceFeesCurrent	10618000
CY2020Q4	tdoc	Other Current Liabilities Clients Guarantees OtherCurrentLiabilitiesClientsGuarantees	7215000
CY2019Q4	tdoc	Other Current Liabilities Clients Guarantees OtherCurrentLiabilitiesClientsGuarantees	3298000
CY2020Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	2419000
CY2019Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	1077000
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	2049000
CY2019Q4	us-gaap	Interest Payable Current InterestPayableCurrent	838000
CY2020Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1627000
CY2019Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	2859000
CY2020Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	3139000
CY2019Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	1263000
CY2020Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	2815000
CY2019Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	2810000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11438000
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5088000
CY2020Q4	tdoc	Accrued Earn Out Current AccruedEarnOutCurrent	4514000
CY2019Q4	tdoc	Accrued Earn Out Current AccruedEarnOutCurrent	0
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	20557000
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5054000
CY2020Q4	tdoc	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	83657000
CY2019Q4	tdoc	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	34440000
CY2020Q4	tdoc	Advances From Financing Companies Customer Payments Due Current AdvancesFromFinancingCompaniesCustomerPaymentsDueCurrent	13453000
CY2020Q4	tdoc	Advances From Financing Companies Customer Payments Due Year One AdvancesFromFinancingCompaniesCustomerPaymentsDueYearOne	7909000
CY2020Q4	tdoc	Advances From Financing Companies Customer Payments Due Year Two AdvancesFromFinancingCompaniesCustomerPaymentsDueYearTwo	2017000
CY2020Q4	tdoc	Advances From Financing Companies Customer Payments Due AdvancesFromFinancingCompaniesCustomerPaymentsDue	23379000
CY2020	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	10823000
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1107000
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	3000
CY2020	us-gaap	Lease Cost LeaseCost	11933000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	10654000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	8134000
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y8M8D
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0564
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	14193000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	14159000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	13946000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	8918000
CY2020Q4	tdoc	Lessee Operating Lease Liability Payments Due Year Five And After Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive	12049000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	63265000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	8685000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	54580000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	475531000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	66702000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	43769000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-566266000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-95476000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-91142000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-9727000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-13979000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-5824000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-575993000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-109455000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-96966000
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-1954000
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	239000
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	27000
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	300000
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	6000
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1605000
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-262000
CY2018	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	2011000
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-322000
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	277000
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2017000
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-60008000
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-5043000
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-499000
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-26775000
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1783000
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	416000
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-3752000
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-4042000
CY2018	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1816000
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-90535000
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-10868000
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1899000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-90857000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-10591000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	118000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.023
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.046
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.048
CY2020	tdoc	Effective Income Tax Rate Reconciliation Acquisition Expenses EffectiveIncomeTaxRateReconciliationAcquisitionExpenses	-0.022
CY2019	tdoc	Effective Income Tax Rate Reconciliation Acquisition Expenses EffectiveIncomeTaxRateReconciliationAcquisitionExpenses	-0.004
CY2018	tdoc	Effective Income Tax Rate Reconciliation Acquisition Expenses EffectiveIncomeTaxRateReconciliationAcquisitionExpenses	-0.013
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.113
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.115
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.165
CY2020	tdoc	Effective Income Tax Rate Reconciliation Executive Compensation EffectiveIncomeTaxRateReconciliationExecutiveCompensation	-0.125
CY2019	tdoc	Effective Income Tax Rate Reconciliation Executive Compensation EffectiveIncomeTaxRateReconciliationExecutiveCompensation	-0.038
CY2018	tdoc	Effective Income Tax Rate Reconciliation Executive Compensation EffectiveIncomeTaxRateReconciliationExecutiveCompensation	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.001
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.002
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.003
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.003
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.022
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.054
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.253
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.415
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.010
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.001
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.007
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.158
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.097
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	497603000
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	158520000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	7016000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	2168000
CY2020Q4	tdoc	Deferred Tax Assets Uncertain Tax Positions DeferredTaxAssetsUncertainTaxPositions	232000
CY2019Q4	tdoc	Deferred Tax Assets Uncertain Tax Positions DeferredTaxAssetsUncertainTaxPositions	352000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	94029000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	14914000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Foreign DeferredTaxAssetsTaxCreditCarryforwardsForeign	5727000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Foreign DeferredTaxAssetsTaxCreditCarryforwardsForeign	5871000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	14666000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	0
CY2020Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	83000
CY2019Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	323000
CY2020Q4	tdoc	Deferred Tax Assets Interest Expenses Carryforward DeferredTaxAssetsInterestExpensesCarryforward	6620000
CY2019Q4	tdoc	Deferred Tax Assets Interest Expenses Carryforward DeferredTaxAssetsInterestExpensesCarryforward	1295000
CY2020Q4	tdoc	Deferred Tax Assets Operating Lease Assets DeferredTaxAssetsOperatingLeaseAssets	13978000
CY2019Q4	tdoc	Deferred Tax Assets Operating Lease Assets DeferredTaxAssetsOperatingLeaseAssets	7492000
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	2917000
CY2019Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	0
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3058000
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	127000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	645929000
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	191062000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	107984000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	121186000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	537945000
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	69876000
CY2020Q4	tdoc	Deferred Tax Liabilities Debt Restructure Costs DeferredTaxLiabilitiesDebtRestructureCosts	105063000
CY2019Q4	tdoc	Deferred Tax Liabilities Debt Restructure Costs DeferredTaxLiabilitiesDebtRestructureCosts	27545000
CY2020Q4	tdoc	Deferred Tax Liabilities Operating Lease Liabilities DeferredTaxLiabilitiesOperatingLeaseLiabilities	12117000
CY2019Q4	tdoc	Deferred Tax Liabilities Operating Lease Liabilities DeferredTaxLiabilitiesOperatingLeaseLiabilities	6889000
CY2020Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	995000
CY2019Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	0
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	2476000
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1667000
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	519397000
CY2019Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	55453000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	640048000
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	91554000
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	102103000
CY2019Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	21678000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	108000000.0
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	13200000
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	65845000
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.36
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.38
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.47
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2912000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Acquisition UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition	15850000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	4990000
CY2020	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	2390000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	21362000
CY2020Q4	us-gaap	Decrease In Unrecognized Tax Benefits Is Reasonably Possible DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible	14100000
CY2020Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	6000000.0
CY2018Q2	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	5500000
CY2018	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	5500000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-485136000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-98864000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-97084000
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	90509000
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	71845000
CY2020	tdoc	Minimum Age Of Employee Eligible Under Plan MinimumAgeOfEmployeeEligibleUnderPlan	P21Y
CY2020	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2020	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04
CY2020	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Amount DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount	300000
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	4900000
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3200000
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2700000

Files In Submission

Name	View Source	Status
0001558370-21-002118-index-headers.html	Edgar Link	pending
0001558370-21-002118-index.html	Edgar Link	pending
0001558370-21-002118.txt	Edgar Link	pending
0001558370-21-002118-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tdoc-20201231.xsd	Edgar Link	pending
tdoc-20201231x10k.htm	Edgar Link	pending
tdoc-20201231x10k004.jpg	Edgar Link	pending
tdoc-20201231x10k_htm.xml	Edgar Link	completed
tdoc-20201231xex10d14.htm	Edgar Link	pending
tdoc-20201231xex10d15.htm	Edgar Link	pending
tdoc-20201231xex10d16.htm	Edgar Link	pending
tdoc-20201231xex10d18.htm	Edgar Link	pending
tdoc-20201231xex10d2.htm	Edgar Link	pending
tdoc-20201231xex21d1.htm	Edgar Link	pending
tdoc-20201231xex23d1.htm	Edgar Link	pending
tdoc-20201231xex31d1.htm	Edgar Link	pending
tdoc-20201231xex31d2.htm	Edgar Link	pending
tdoc-20201231xex32d1.htm	Edgar Link	pending
tdoc-20201231xex32d2.htm	Edgar Link	pending
tdoc-20201231xex4d11.htm	Edgar Link	pending
tdoc-20201231_cal.xml	Edgar Link	unprocessable
tdoc-20201231_def.xml	Edgar Link	unprocessable
tdoc-20201231_lab.xml	Edgar Link	unprocessable
tdoc-20201231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TDOC
Teladoc Health, Inc. Stock $tdoc

2020 Form 10-K Financial Statement

#000155837021002118 Filed on March 01, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TDOC Teladoc Health, Inc. Stock $tdoc

2020 Form 10-K Financial Statement

#000155837021002118 Filed on March 01, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TDOC
Teladoc Health, Inc. Stock $tdoc